Article
Predictors of the response to gefitinib in refractory non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2005
Kim Kyu-Sik, Jeong Ju-Yeon, Kim Young-Chul, Na Kook-Joo, Kim Yun-Hyeon, Ahn Sung-Ja, Baek Sun-Mi, Park Chang-Soo, Park Chang-Min, Kim Yu-Il, Lim Sung-Chul, Park Kyung-Ok
Abstract excerpt
Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has a response rate of 10% to 20% in refractory non-small cell lung carcinoma. Although female gender, adenocarcinoma, and never having smoked are possible markers of a favorable response, mutations of the EGFR gene have also been reported to be highly significant predictors of response. Seventy patients with relapsed non-small cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.